MDXG - MiMedx sees Q3 sales as high as $64M

On a preliminary basis, MiMedx Group (MDXG) expects Q3 sales of $61M - 64M, down 28 - 31% from a year ago although the Q3 2019 sales included a $21.5M benefit from a change in its methods of revenue recognition from the time of cash collection to the time of shipment.Beginning today, certain executives will hold conference calls with institutional investors. Presentation materials can be accessed on its website under "Investor Relations."

For further details see:

MiMedx sees Q3 sales as high as $64M